TP53 mutation is a well-established prognostic biomarker associated with poor prognosis and an inferior response to standard front-line therapies. In addition, risk stratification models have been established, including Ki67 index, age, lactate dehydrogenase levels, performance status, and white blood cell count.
Learn more about MCL.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ann S. LaCasce. Fast Five Quiz: Non-Hodgkin's Lymphoma: Mantle Cell Lymphoma Practice Essentials - Medscape - May 22, 2023.